Showing results (411-420 of 458) with videos related to
Sort By:
Pageof 46
Cancer Research|February 22, 2012
Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicityKristopher R Bosse, Sharon J Diskin, Kristina A Cole, et al.Research Square|April 22, 2024
Interleukin-15-armored GPC3-CAR T cells for patients with solid cancersDavid Steffin, Nisha Ghatwai, Antonino Montalbano, et al.The New England Journal of Medicine|May 9, 2008
Chromosome 6p22 locus associated with clinically aggressive neuroblastomaJohn M Maris, Yael P Mosse, Jonathan P Bradfield, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2021
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT ConsortiumSteven G DuBois, M Meaghan Granger, Susan Groshen, et al.Cancer Cell|September 13, 2017
Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk NeuroblastomaKristopher R Bosse, Pichai Raman, Zhongyu Zhu, et al.Nature|November 13, 2015
Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphismDerek A Oldridge, Andrew C Wood, Nina Weichert-Leahey, et al.Cancer Discovery|February 10, 2021
Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK InhibitionBrittany B Campbell, Melissa A Galati, Simone C Stone, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2018
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory NeuroblastomaSteven G DuBois, Yael P Mosse, Elizabeth Fox, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2019
CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain TumorsRobbie G Majzner, Johanna L Theruvath, Anandani Nellan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2026
PRECLINICAL ACTIVITY OF THE B7-H3- TARGETING ANTIBODY-DRUG CONJUGATE (ADC) VOBRAMITAMAB DUOCARMAZINE (VOBRA DUO) IN PEDIATRIC SOLID TUMORSEdward Favours, Haiying Tang, Peyton Wong, et al.Pageof 46